Given that the pathogenesis of epidermal growth factor receptor inhibitor-induced cutaneous toxicity—primarily mediated through inhibition of the epidermal growth factor receptor (EGFR) signaling pathway in keratinocytes and follicular epithelium—exhibits remarkable consistency, corresponding management strategies demonstrate broad generalizability and translatability across various malignancies (e.g., non-small cell lung cancer, colorectal cancer, and head and neck cancer). This evidence concerns the gene EGFR and non-small cell lung carcinoma.